Atypical intraepidermal melanocytic proliferations (AIMP)
INTRODUCTION
The presence of cytologic atypia or pagetoid scatter within a melanocytic proliferation overlying sun-damaged skin can be highly concerning for evolving melanoma in situ (MIS). To distinguish benign lesions from those that are malignant, immunohistochemical stains are often used to look for a lentiginous proliferation of melanocytes along the dermal-epidermal junction, which is suggestive of the radial growth phase of melanoma. In cases where immunohistochemical staining and the histologic features of the lesion are insufficient for a definitive diagnosis of cancer, a descriptive diagnosis of atypical intraepidermal melanocytic proliferation (AIMP) is reported, which informs the clinician that the lesion has certain features that are concerning for evolving melanoma and that it should be widely excised. The most commonly used immunohistochemical stains for distinguishing between AIMP and MIS are S100, Melan-A, and microphthalmia-associated transcription factor (MITF). However, each immunostain has its own advantages and limitations.
The S100 antigen is expressed in melanocytes making it an excellent marker for mestastatic melanoma. However, the diagnostic utility of this immunostain is limited by broad expression of its target antigen in other cell types of neural crest origin and its failure to stain up to 7% of melanomas. [1] [2] [3] [4] [5] [6] Melan-A (and its closely related antigen MART-1) is a commonly used alternative to S100 because of its perceived high sensitivity and specificity for melanocytes. Recent studies, though, have suggested that Melan-A overestimates the number of melanocytes in solar lentigenes and MIS, and stains keratinocytes in the setting of inflammation. [7] [8] [9] [10] [11] [12] [13] [14] MITF is a newer melanocytic marker that may allow for more accurate estimation of the number of melanocytes within the epidermis. 14 It is a nuclear antigen that encounters less interference from cytoplasmic melanin pigment on routine immunohistochemical staining using DAB chromogen and may have the advantage of providing valuable prognostic information for the treating clinician as higher levels of this protein are found in metastatic melanoma and are associated with a decreased response to chemotherapeutics. 15 In this study, we evaluated the percentage of cells stained by S100, Melan-A, and MITF for a cohort of AIMP lesions. Each immunostain was compared to the percentage of epidermal melanocytes estimated to be present by conventional hematoxylin and eosin staining. We hypothesized that there would be discrepancies in the number of epidermal melanocytes estimated by each antibody. The question of staining variability in AIMP lesions has not previously been evaluated and is especially germane to pathologists reviewing these cases as the extent of epidermal staining may influence the decision to call a lesion benign or malignant.
MATERIALS AND METHODS

Atypical Intraepidermal Melanocytic Proliferation
The descriptive diagnosis of AIMP is specifically used for melanocytic lesions that have random cytologic atypia with one or more of the following histologic features: upward migration of melanocytes within the epidermis and melanocyte contiguity. The diagnosis of melanoma in situ was avoided in these cases because these lesions failed to demonstrate uniform atypia and a continuous proliferation of melanocytes along the dermal-epidermal junction on routine hematoxylin and eosin staining. Morphologic evaluation on hematoxylin and eosin sectioning is the standard technique for identifying cytologic atypia and near confluent growth along the dermal-epidermal junction, which characterize AIMP. In this study, we chose morphologically well-characterized AIMP lesions and compared the detection of various melanocytic markers with the number of morphologically recognizable melanocytes on hematoxylin and eosin, which was used as a reference or "gold standard" for melanocyte detection in AIMP.
Cases
Tissue samples (n = 49) of morphologically wellcharacterized AIMP biopsied between 2005 and 2010 were retrieved from the archives of the Department of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania. Slides were pulled for these cases and reviewed to confirm the diagnosis in each case and tissue blocks were cut for immunostaining.
Immunostaining
All tissue was fixed in phosphate-buffered neutral formaldehyde (10%) for 12-36 hours and embedded in paraffin. Four-micron-thick sections were mounted on Probe-on slides and used for immunohistochemical staining. Antibodies against S100 (polyclonal, 1:3000, Dako, Carpinteria, CA), MITF (clones D5 and C5, 1:200; NeoMarkers, Fremont, CA), and Melan-A (clone A103, 1:25, Dako, Carpinteria, CA) were applied after antigen retrieval and a standard avidin-biotin complex method was used on an autostainer (Techmate 1000, Ventana/Biotek Medical Systems, Winooski, VT). Slides were microwaved for 4 minutes twice in 1 · HIER buffer (Lab Vision, Fremont, CA) for Melan-A and boiled in 1 · EDTA buffer (Lab Vision, Fremont, CA) for 20 minutes for MITF. Immunoreactivity was evaluated under the light microscope and was considered specific when cytoplasmic for S100 and Melan-A, and nuclear for MITF. For practical reasons, cases were considered positive only when unequivocal specific reactivity was found in a minimum of 5% of the tumor cells. Epithelioid melanomas known to express the above markers were used as positive controls. A section of each block was incubated with normal mouse serum (prediluted, Ventana Medical systems, AR) for our negative controls.
Assessment and Statistical Analysis
Three pathologists independently examined each of the slides and were blinded to the results of their colleagues. Each reviewer estimated the percentage of cells within the basal layer of the epidermis that were melanocytes at 200· to 400· magnifications. All percentages reported in this article refer to the basal layer of the epidermis and were calculated in lesional areas that were identified by the reviewer to have the highest density of melanocytes. For each specimen, we calculated the difference between the percentage of melanocytes estimated by immunostaining and the percentage estimated by morphology on hematoxylin and eosin. The mean difference was reported for each melanocyte stain (vs. hematoxylin and eosin), and the statistical significance of this calculation was evaluated using a Wilcoxon signed rank test after standard diagnostics revealed that not all of the immunostains had a normal distribution of values. All statistical analyses were performed using the computer program Stata 11 (StataCorp, College Station, TX).
RESULTS
This study examined 49 AIMP lesions collected between 2005 and 2010 by the Department of Pathology at the Hospital of the University of Pennsylvania. Thirty-one of the lesions were biopsied from women and 18 were biopsied from men. The mean patient age was 53 years old (range: 14-94). Case lesions were taken from many different parts of the body including the head and neck (n = 13), abdomen/ chest/back (n = 12), extremities (n = 11), and genitalia (n = 13). Insufficient tissue existed for 2 of the cases to perform all 3 immunohistochemical stains. Melan-A was selected for one of these cases and MITF and S100 for the other to balance the use of the different melanocyte stains.
Melan-A estimated the highest proportion of melanocytes and S100 the fewest in 47 of the 49 lesions ( Figs. 1-3) . The estimated percentage of melanocytes was 23.3% (95% confidence interval: 18.3-28.3; P , 0.001) higher for Melan-A compared with hematoxylin and eosin staining. Melanocyte estimates were similar for hematoxylin and eosin and MITF (P = 0.15) although S100 estimated 21.8% (95% confidence interval: -27.5 to -16.1; P , 0.001) fewer melanocytes than hematoxylin and eosin ( Table 1 ).
DISCUSSION
AIMPs are frequently encountered in clinical practice and can be difficult to distinguish from melanoma in situ. 16 Immunohistochemical staining is an important diagnostic tool utilized by pathologists to help them make this distinction. However, certain markers and their variable staining may affect these diagnoses by misrepresenting the number of melanocytes present. Our study follows up on recently published data showing that Melan-A overestimates the number of melanocytes within sun-damaged skin. 13 We sought to determine if these findings for Melan-A were also true for AIMP lesions by comparing this antibody to other commonly used immunostains for melanocytic tumors along with traditional hematoxylin and eosin staining.
Melan-A seemed to stain the greatest number of cells in 47 of the 49 specimens examined and the estimated percentage of epidermal melanocytes by Melan-A was 23.3% higher than the percentage observed on hematoxylin and eosin. These findings suggest that Melan-A overestimates the number of melanocytes in AIMP compared to S100, MITF, and hematoxylin and eosin. This finding is consistent with previous studies examining the number of cells stained in pigmented actinic keratoses, solar lentigenes, and MIS by several of the most commonly used melanocyte stains in clinical practice. 8, 13 Previous studies have hypothesized that Melan-A is taken up by a small percentage of keratinocytes in addition to its target cell, the melanocyte. 9 This could partially explain the increased amount of staining observed with Melan-A. However, we believe the distribution of the immunostain target antigen within cells may provide an alternative explanation for our observations. Both Melan-A and S100 are cytoplasmic proteins. Melanocytes have long dendritic processes of cytoplasm that encircle nearby keratinocytes to help facilitate the transfer of melanin pigment to these cells (Fig. 4) . Consequently, the staining of antigen within these cytoplasmic extensions may encircle neighboring keratinocytes and thus artificially increase the perceived number of melanocytes. In addition, we have also recently observed Melan-A reactivity in some schwannomas in our practice (data not shown). The melanocytic specificity of Melan-A is also questioned in those cases.
MITF staining of AIMP lesions estimated a similar number of melanocytes as morphologic evaluation on hematoxylin and eosin. In addition to its high concordance with morphologic assessment in identifying melanocytes, the MITF immunostain may also be the easiest to interpret amongst the 3 because of its clean nuclear expression and minimal interference from cytoplasmic melanin pigment. Furthermore, because of its nuclear location, it would not stain dendritic processes of melanocytes, which could "pseudostain" the adjacent keratinocytes as in the case of Melan-A staining. Therefore, it may be the most helpful and reliable melanocytic marker in the epidermis for these melanocytic lesions (Fig. 4) . MITF along with the other immunohistochemical stains also has the advantage over Figure 2 shows the distribution of percentages for each of the 3 immunohistochemical stains and hematoxylin and eosin staining. Melan-A estimated a higher percentage of melanocytes than S100 and MITF. S100 consistently stained fewer cells in the basal layer of the epidermis than the other 2 immunostains. hematoxylin and eosin. The percentage of melanocytes in the basal layer of the epidermis was estimated by immunohistochemistry (Melan-A, MITF, S100). These percentages were then compared with the percentage observed on hematoxylin and eosin and the difference in estimates is represented in the above graph. Figure 3 illustrates that Melan-A consistently estimates a higher percentage of melanocytes than the other 2 immunostains and hematoxylin and eosin. S100 stained the fewest cells in 47 of the 49 cases reviewed. 
The percentage of stained cells in the basal layer of the epidermis identified by immunohistochemistry was compared with hematoxylin and eosin for all 49 specimens and the mean difference for each immunostain is listed in Table 1 . Positive percentages indicate that a particular immunostain estimated a higher number of melanocytes than hematoxylin and eosin with the reverse being true for negative percentages. The P values were calculated by performing a Wilcoxon signed rank test comparing the percentage of melanocytes estimated by each immunostain to the percentage estimated on hematoxylin and eosin for all 49 specimens.
CI, confidence interval.
hematoxylin and eosin of helping pathologists to identify melanocyte pagetoid scatter within the epidermis, which can be a concerning histologic feature for melanoma in situ. S100 is also predominantly a cytoplasmic antigen, and is well known for its high sensitivity in melanocytes. Our finding of significantly fewer S100 positive melanocytes in the epidermis than those counted on hematoxylin and eosin stains or those detected by MITF is interesting (Figs. 2, 3 ). S100 negative melanocytes and melanomas are well documented. 17 The decreased staining with S100 in the epidermal melanocytes may reflect reduced expression of this antigen within AIMP lesions. Thus, this finding suggests that epidermal melanocytes in AIMP express MITF, a master transcription factor required in early melanogenic differentiation, but not S100. The other possibility for this finding would be poor affinity of the S100 polyclonal antibody for its target antigen. 17 However, this is unlikely since this antibody is one of the most commonly used in vitro diagnostic antibodies. It has been used in our laboratory for a long time and such decreased affinity or sensitivity has not been observed in other types of specimens and lesions. The biologic significance of these MITF positive, S100-negative melanocytes/premelanocytes in AIMP remains to be clarified. In any case, caution should be taken when using S100 to interpret AIMP as this immunohistochemical stain may inappropriately reduce the number of melanocytes seen in these lesions leading to difficulty in reaching the correct diagnosis.
Overall, our findings confirm the results of similar recent studies showing that Melan-A/MART-1 may overestimate melanocytic staining in intraepidermal melanocytic lesions and that MITF may be the most reliable marker in this setting. This study is the first to extend these claims to AIMPs and highlights the potential concern that staining these lesions with Melan-A may cause pathologists to overdiagnose melanoma in situ. Additionally, S100 staining in our study was far lower than the other 2 immunostains and hematoxylin and eosin, which suggests that this stain is unreliable in AIMPs.
